<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567290</url>
  </required_header>
  <id_info>
    <org_study_id>12345</org_study_id>
    <nct_id>NCT04567290</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome</brief_title>
  <acronym>TICA-MASTICA</acronym>
  <official_title>Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalario La Concepcion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalario La Concepcion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to determine the pharmacodynamic performance in the first hour measured with&#xD;
      verifynow, of the conventional ticagrelor loaded dose versus chewed ticagrelor in patients&#xD;
      with acute coronary syndrome treated with percutaneous coronary intervention&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>1 hour</time_frame>
    <description>Platelet reactivity measured with VerifyNow (PRU)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (MACCE)</measure>
    <time_frame>30 days</time_frame>
    <description>Composite outcome: made by major adverse cardiac and cerebrovascular events: all-cause death, repeat myocardial revascularization, stroke, myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcome</measure>
    <time_frame>30 days</time_frame>
    <description>Composite outcome: major bleeding, AND nonmajor clinically relevant (NMCR) bleeding both by ISTH definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy (long term)</measure>
    <time_frame>1 year</time_frame>
    <description>Composite outcome: number of participants with major adverse cardiac and cerebrovascular events (MACCE) (previously defined)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity on treatment rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Inhibition of platelet aggregation (IPA) measured by VerifyNow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Chewed ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor pills. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement and after signed informed consent. Patients will be asked to chew, but not to swallow, during at least 40 seconds in presence of investigation staff.&#xD;
Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Swallowed ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor integral tablet. The 180 mg loading dose will be administered as soon as possible by investigation staff after a baseline VerifyNow measurement is drawn. Patients will swallow the loading dose followed by 25-40 ml of water.&#xD;
Drug: ticagrelor (Brilinta) 90 mg tableta, 2 tablets swallowed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chewed ticagrelor</intervention_name>
    <description>Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets</description>
    <arm_group_label>Chewed ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Swallowed ticagrelor</intervention_name>
    <description>Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets</description>
    <arm_group_label>Swallowed ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients presenting to the emergency department with acute coronary syndrome for&#xD;
             percutaneous coronary intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Known coagulopathy, bleeding diathesis, or active bleeding&#xD;
&#xD;
          -  History of recent gastrointestinal or genitourinary bleeding within 2 months&#xD;
&#xD;
          -  Previous therapy with clopidogrel, prasugrel, or ticagrelor&#xD;
&#xD;
          -  Previous treatment with glycoprotein IIb/IIIa inhibitors or during interventional&#xD;
             procedure&#xD;
&#xD;
          -  Major surgery within 6 weeks&#xD;
&#xD;
          -  History of intracranial bleeding or intracraneal neoplasm&#xD;
&#xD;
          -  Suspected aortic dissection&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Severe hemodynamic instability or cardiogenic shock&#xD;
&#xD;
          -  Resuscitated cardiac arrest&#xD;
&#xD;
          -  Use of vitamin K anticoagulants or novel oral anticoagulants (NOACs) within 7 days&#xD;
&#xD;
          -  Life expectancy &lt;1 year&#xD;
&#xD;
          -  Known severe liver or renal disease, GFR estimated by CKD-EPI &lt;30 ml/min/1.73 m2&#xD;
&#xD;
          -  Known HIV treatment&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL&#xD;
&#xD;
          -  Platelet count &lt;100,000/L&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known allergy to ticagrelor&#xD;
&#xD;
          -  Refusal to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos Felipe Barrera Ramírez, MD</last_name>
    <phone>8441602269</phone>
    <email>carlosfbarrera@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital La Concepción</name>
      <address>
        <city>Saltillo</city>
        <state>Coahuila</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Felipe Barrera Ramírez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ticagrelor</keyword>
  <keyword>Platelet aggregation inhibitors</keyword>
  <keyword>VerifyNow</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

